NCT05248945View on ClinicalTrials.gov

DDI Study of Evobrutinib and Carbamazepine

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Healthy
Interventions
DRUG

Evobrutinib

Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.

DRUG

Carbamazepine

Participants will receive carbamazepine tablet twice daily from Days 2 to 25.

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY